GSK2190915 Pediatric Study

Exclusion Criteria

• •Subjects who have changed their asthma medication, dose or regime within 4 weeks of screening
• •Administration of anti -leukotriene therapies for 14 days before screening and during the study.
• •Any medical condition or circumstance making the volunteer unsuitable for participation in the study.
• •Any clinically relevant abnormality identified on the screening medical assessment.
• •Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved within 4 weeks of screening and led to a change in asthma management.
• •Administration of any vaccinations within 2 weeks of screening or during the study
• •Parent/guardian has history of psychiatric disease, intellectual deficiency, substance abuse, or other condition which will limit the validity of consent to participate in this study.
• •Any adverse reaction including immediate or delayed hypersensitivity to any component of study drug
• •A subject will not be eligible for this study if he/she is an immediate family member of the participating Investigator, sub-Investigator, study coordinator, or employee of the participating Investigator.
• •Children who are wards of the state or government.
• •The subject has a screening QTc value of \>450msec, PR interval outside the range 120 to 220msec or an ECG that is not suitable for QT measurements.